Crystalline Form I of Ibrutinib
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2015/064432, filed Dec 8, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,751,889 | Crystalline Form I of Ibrutinib In force · High confidence | Crystal Pharmatech Co., Ltd. and Suzhou Pengxu Pharmatech Co., Ltd. | In force | High confidence | ||
| US 9,957,240 | Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof In force · High confidence | Crystal Pharmatech Co., Ltd. and Suzhou Pengxu Pharmatech Co., Ltd. | In force | High confidence | ||
| US 10,508,087 | Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof In force · High confidence | Crystal Pharmatech Co., Ltd. and Suzhou Pengxu Pharmatech Co., Ltd. | In force | High confidence | ||
| US 10,246,418 | New Crystal Form of Lenvatinib Methanesulfonate Salt and Preparation Method Thereof In force · High confidence | Crystal Pharmatech Co., Ltd. | In force | High confidence | ||
| US 10,138,239 | Preparation Method of Crystalline Form a of PCI-32765 Lapsed Nov 27, 2022 on the fee record Ended Nov 27, 2022 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Nov 27, 2022 on the fee record | Ended Nov 27, 2022 | High confidence | |
| US 10,196,395 | Crystalline Form Alpha of IPI-145 and Preparation Method Thereof Lapsed Feb 5, 2023 on the fee record Ended Feb 5, 2023 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Feb 5, 2023 on the fee record | Ended Feb 5, 2023 | High confidence | |
| US 10,233,144 | Crystalline Form of AHU377, Preparation Method and Use Thereof Lapsed Mar 19, 2023 on the fee record Ended Mar 19, 2023 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Mar 19, 2023 on the fee record | Ended Mar 19, 2023 | High confidence | |
| US 10,246,437 | New Crystal Form of Neratinib Maleate and Preparation Method Therefor Lapsed Apr 2, 2023 on the fee record Ended Apr 2, 2023 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Apr 2, 2023 on the fee record | Ended Apr 2, 2023 | High confidence | |
| US 10,273,262 | Crystalline Form a of Obeticholic Acid and Preparation Method Thereof Lapsed Apr 30, 2023 on the fee record Ended Apr 30, 2023 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Apr 30, 2023 on the fee record | Ended Apr 30, 2023 | High confidence | |
| US 10,308,641 | Novel Crystal Form of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]DIOXOLE-5-YL)CYCLOPROPANE FORMAMIDO)-3-Methylpyridine-2-YL)BENZOIC Acid and Preparation Method Thereof Lapsed Jun 4, 2023 on the fee record Ended Jun 4, 2023 · High confidence | Crystal Pharmatech Co., Ltd. | Lapsed Jun 4, 2023 on the fee record | Ended Jun 4, 2023 | High confidence | |
| 7 more patents in this group · Pro | ||||||
10 of 17 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 17, including 12 expired.
4 of these are in force and held by Crystal Pharmatech Co., Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.